NCT07309094 Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
| NCT ID | NCT07309094 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cardenal Herrera University |
| Condition | Chronic Kidney Disease stage3 |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2023-09-15 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2023-09-15 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The accumulation of fat tissue around the organs in conditions of obesity or diabetes accelerates the production of pro-inflammatory factors that may worsen the kidney and heart damage. New antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), have proven beneficial effects on the kidney and heart due to several mechanisms, including anti-inflammatory actions and a potential action on the fat tissue. The aim of this study is to assess the link between adiposopathy and CKD, by investigating the changes in adiposopathy measures throughout treatment with GLP-1RA to a sample of patients with CKD.
Eligibility Criteria
Inclusion Criteria: * \> or = 18 years of age * diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis * had uncontrolled T2DM, CVDs and/or obesity * willing to participate in the study and sign informed consent Exclusion Criteria: * Age \<18 years * pregnancy * CKD in stage G5 or G4 candidate for dialysis * neuropsychiatric diseases preventing the patient from understanding the benefits/risks associated with the project * refusal to participate and/or consent revocation were considered as exclusion criteria
Contact & Investigator
Luis D'Marco, MD, PhD
PRINCIPAL INVESTIGATOR
Cardenal Herrera University
Frequently Asked Questions
Who can join the NCT07309094 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Chronic Kidney Disease stage3. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07309094 currently recruiting?
Yes, NCT07309094 is actively recruiting participants. Contact the research team at ana.checaros@uchceu.es for enrollment information.
Where is the NCT07309094 trial being conducted?
This trial is being conducted at Valencia, Spain.
Who is sponsoring the NCT07309094 clinical trial?
NCT07309094 is sponsored by Cardenal Herrera University. The principal investigator is Luis D'Marco, MD, PhD at Cardenal Herrera University. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.